Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Patient demographics. by Katrine Carlsen (5477300)

Subjects:

Alpha diversity measures across all 727 samples. by Katrine Carlsen (5477300)

Subjects:

STORMS microbiome reporting checklist. by Katrine Carlsen (5477300)

Subjects:

Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales. by Vincenza Tarantino (182506)

Puriton had the tendency of decreasing expressions of Th1 cell-related cytokines such as IFN- by So-Hyeon Bok (8066696)

Forest plots illustrate the mean difference in; (A) creatinine clearance, (B) eGFR, (C) BUN, and (D) shows relative risk in ARF. by Mohamed R. Abdelraouf (21501468)

Means scores of CAM and CAM-MYCS. by Senay Yildirim-Kahriman (22693464)

Variation of the most appropriate p value significance threshold with different ratios of the standard deviations and sample sizes. by Farrokh Habibzadeh (12256529)

No significant diurnal rhythmicity of short chain fatty acids in the blood was observed. by Weiran Shan (16969688)

Recruitment flow diagram of the current study. by Somayeh Momenyan (10111603)

“…Phase 1 EQ-VAS decreases were associated with female sex, lower somatic symptom, fewer comorbidities, lack of expectation for a fast recovery, higher ISS, higher injury pain, neck, spine/back or lower extremity injuries. …”

Chitosan-Based Thermal-Coagulation Hydrogel System Driven by Multiple Interactions: Oxidation-Induced Fast Gelation and Enhanced Performance by Yifan Liu (219681)

Subjects: